Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension

Summary

AMB-220-E is an international, multicenter, open-label study examining the long-term safety of ambrisentan (BSF 208075) in subjects who have previously completed Myogen study NCT00046319, "A Phase II, Randomized, Double-Blind, Dose-Controlled, Dose-Ranging, Multicenter Study of BSF 208075 Evaluating Exercise Capacity in Subjects with Moderate to Severe Pulmonary Arterial Hypertension".

Timeline

Start

2003-04

Primary completion

2009-12

Completion

2009-12

Drugs

Indications